With increasing donor age, the potential of transmitting diseases from donor to recipient reaches new dimensions. Potentially transmittable diseases from donors include infections, congenital disorders, and acquired illnesses like autoimmune diseases or malignancies of hematological or nonhematological origin. While established nonmalignant or malignant diseases might be easy to discover, earlystage hematological diseases like CML, light-chain multiple myelomas, aleukemic leukemias, occult myelodysplastic syndromes and other malignant and nonmalignant diseases might not be detectable by routine screening but only by invasive, new and/or expensive diagnostic tests. In the following article, we propose recommendations for donor work-up, taking into consideration the age of the donors. In contrast to blood transfusions, stem cells from donors with abnormal findings might still be acceptable for HCT, when no other options are available and life expectancy is limited. This issue is discussed in detail in relation to the available donor and stem cell source. Finally, the recommendations presented here aim at harmonized worldwide work-up for donors to insure high standard quality.
Summary:
With increasing donor age, the potential of transmitting diseases from donor to recipient reaches new dimensions. Potentially transmittable diseases from donors include infections, congenital disorders, and acquired illnesses like autoimmune diseases or malignancies of hematological or nonhematological origin. While established nonmalignant or malignant diseases might be easy to discover, earlystage hematological diseases like CML, light-chain multiple myelomas, aleukemic leukemias, occult myelodysplastic syndromes and other malignant and nonmalignant diseases might not be detectable by routine screening but only by invasive, new and/or expensive diagnostic tests. In the following article, we propose recommendations for donor work-up, taking into consideration the age of the donors. In contrast to blood transfusions, stem cells from donors with abnormal findings might still be acceptable for HCT, when no other options are available and life expectancy is limited. This issue is discussed in detail in relation to the available donor and stem cell source. Finally, the recommendations presented here aim at harmonized worldwide work-up for donors to insure high standard quality. Often being the only curative option, HCT is increasingly used in the treatment of a variety of malignant and nonmalignant hematological diseases.
1,2 Improved results following advances in HLA typing, new immunosuppressive protocols and better supportive care as well as the use of reduced conditioning protocols have increased the frequencies of HCT and shifted patients and related donors towards older ages. [3] [4] [5] [6] [7] [8] [9] HCT is now performed worldwide, several thousand times a year, and complicated logistics have been set up to identify healthy donors for our patients. 10, 11 Increases in frequencies and age, however, raise questions on donor and recipient safety. Although both aspects are equally important, the potential of transmitting diseases from donor to recipient reaches new dimensions with increasing donor age, since diseases and most malignancies, in particular, tend to increase in prevalence with increasing age. Potentially transmittable diseases from donors include infections (bacteria, viruses, fungi, parasites), congenital disorders (eg hemoglobinopathies), acquired illnesses like autoimmune diseases, or malignancies of hematological or nonhematological origin (Table 1) . Infections are caused by the infusion of pathogens residing intracellularly and/or in the plasma. Congenital disorders or autoimmune diseases result from the permanent engraftment of hematopoietic stem cells (congenital disorders) or immune cells (autoimmune diseases) in the recipient. Malignant cells contaminating the graft either engraft (hematological malignancies) or metastasize (nonhematological malignancies) in the new host.
While established nonmalignant or malignant diseases may be easy to discover, early-stage hematological diseases like CML, light-chain multiple myelomas, aleukemic leukemias, occult myelodysplastic syndromes and other malignant and nonmalignant diseases might not be detectable by routine screening, rather only by invasive, new and/or expensive diagnostic tests. Such procedures include not only imaging methods like CT or MRT but also PCR and cytogenetics that allow the detection of nonmalignant and malignant diseases even in subclinical stages. However, the financial burden has also increased and extensive screening procedures might not be feasible considering the cost-benefit aspect. Furthermore, the need to harmonize worldwide work-up for donors to ensure high standards is urgently needed.
This editorial would like to focus on the issue of donor disease transmission by HCT, analyzing the approximate frequency of such complications, the reports on donor disease transmission and the recommendations on donor screening available today. This should be the platform to discuss potential improvements in screening hematopoietic stem cell donors.
Transmission of pathogens
Screening methods to prevent transmission of infectious agents in HCT follow identical strategies as for blood transfusions. 12 Infectious complications in HCT, however, differ substantially from the ones encountered after blood transfusions. Additional infectious agents, such as CMV, EBV or other herpes viruses, are of importance and need to be screened for appropriate donor selection or post transplant management. They are of increasing importance and are determinants for morbidity and mortality in HCT. 42 In addition, pathogens of viral, bacterial, fungal or parasitic origin reside even in asymptomatic donors and, depending on the host immune system, cause infections with or without disease in the immunosuppressed recipient. These pathogens may be recognized only indirectly by positive serological titers or by PCR. Furthermore, stem cell donors are often unique to the recipients and, except for cryopreserved products, their grafts infused without sterility tests available.
Viruses
Viruses like HIV type I and II, hepatitis B, C and the leukemia-associated human T-lymphotropic virus type I and II are the most frequent and serious causes of infections transmittable by blood and marrow products. 12, 13 With the screening methods used today, the risk for transmission of these viruses from a stem cell donor to a recipient is likely to be very low. The real risk is very difficult to assess and can only be extrapolated from blood transfusions. In the early 1980s, the incidence of transfusion transmitted HIV was greater than one case per 1000 units, whereas the current risk is less than one case per 2 million units. Using single unit nucleic acid testing (NAT) this risk might even be one per 5 million units. 12, 43, 44 Similar improvements have been made in the diagnostic tests for HBV and HCV, two viruses carrying significant morbidity and mortality, substantially reducing the risk of transmission. 43, 44 All routine screening recommendations include these pathogens and donors with such infections are not candidates for blood donation. 45, 46 Although hepatitis B or C infection is an absolute exclusion criterion for blood donation, it may not be a contraindication for stem cell donation. Crucial points for such individual decisions are the infectious status of the recipient, the lack of an alternative compatible donor, a limited life expectancy of the recipient and the full donor and recipient informed consent.
While all viruses residing in the blood or bone marrow are potentially transmissible from a donor to a recipient, the clinical consequences of such a transmission vary.
The most recent addition to the list of viruses transmittable by transfusion is the West Nile virus, a flavivirus transmitted by birds to humans through the bite of mosquitos. It can cause significant morbidity and mortality in elderly patients, in particular. Furthermore, no specific treatment or vaccination is currently available. Blood product transfusion, transmission through solid organ transplantation and transplacental transmission have been recognized as modes of transmission. 47, 18, 19 No reports are available with regard to transmission through stem cell transplantation.
CMV is the most important infection determining the outcome of HCT and donor CMV status is the most important risk determinant and it is, therefore, of crucial importance in the selection of donors. Recommendations for prevention and management of CMV infections have been established by the CDC as well as by the Infectious Diseases Working Party of the EBMT.
14 These guidelines recommend the use of CMV-seronegative donors for seronegative recipients whenever possible. In seropositive patients, the choice of the proper donor is controversial. In a recent study, seropositive patients undergoing unrelated non-T-cell-depleted HCT had an improved survival if they received a graft from a seropositive donor. 15 However, another study from the NMDP failed to find such a protective effect. 16 No protective effect of donor serological status was found if the donor was an HLA-identical sibling in CMV-positive recipients. In contrast to the situation in blood transfusion, lack of appropriate HCT donors may still force the physician to accept suboptimal CMV donor/ recipient serological combinations.
Serologic testing of EBV is generally not recommended but is performed at many transplant centers. EBV has a limited role as a direct pathogen after SCT but is the cause of Post Transplantation Lymphoproliferative Disease (PTLD), a complication associated with high mortality. Several reports have indicated that the risk for PTLD is increased if an EBV-seropositive donor is used for an EBVseronegative patient, particularly after an unrelated or mismatched SCT.
Human herpesvirus 8 is associated with Kaposi's sarcoma and can be transmitted by organ grafts and blood transfusions. The prevalence varies greatly between different geographical areas. No clear recommendations exist with regard to routine donor testing but it may be indicated if a donor comes from a high prevalence area. Testing of donor serostatus for HSV and VZV is currently not routine in most centers since HSV transmission by marrow or stem cell products has not been documented. Transmission of parvovirus B19 by bone marrow transplantation has been described. 17 Parvovirus can cause pancytopenia, but the overall risk of parvovirus B19 infection and disease transmitted by HCT is very limited and routine testing is not recommended.
Bacteria
Transmission of bacteria to recipients usually occurs through contamination of the graft and more seldom from the blood or bone marrow of the donor itself. Contamination rates of about 1 per 1-3000 U as observed in blood products seem to be excessive, although no exact information is available. 48 Cryopreserved autologous grafts or cord blood might be contaminated with Gram-positive or less frequently with Gram-negative bacteria.
Brucellosis has also been reported to be transmitted by HCT20. Although the infection may be treated successfully with antibiotic therapy, donor and recipient should be screened for brucellosis in countries at high risk.
Fungi
Transmission of fungal infection is usually caused by contamination of the graft during harvest or manipulation. Adequate anti-fungal therapy might allow the use of such grafts in the absence of further options.
Parasites
Toxoplasmosis is becoming the most frequent complication caused by parasites after HCT. Patients at risk are primarily seropositive patients in whom reactivation of toxoplasma might occur during immunosuppression. 21 Transmission from the stem cell donor seems to be rare. 22 Transfusion-transmitted malaria has been reported previously and represents a potential problem in blood transfusions and HCT. 23, 24 Malaria as a complication in HCT is extremely unusual. One case of Plasmodium falciparum transmission after sibling allogeneic HCT and two of Plasmodium vivax, one after unrelated HCT and one recrudescence after autologous HCT, have been reported. [24] [25] [26] The risk is likely to be dependent on the geographical location of both patient and donor. In malaria nonendemic areas such as the United States, the estimated incidence of malaria transmission by blood transfusion is one per one million units. This is lower than that of Hepatitis B, bacterial infections and is similar to that of hepatitis C or HIV after the introduction of NAT. However, in other geographical areas, the risk is likely to be higher, although no reliable risk estimation exists. Nosocomial malarial transmission is well recognized. It can follow needle-stick injuries, and via the use of a single syringe on heparin locks. 49 Since there is no reliable laboratory test to screen for malaria, prevention depends on the exclusion of potentially infected donors during the donor interview. A history of malaria should not result in deferral of the donor, especially if the donor has been asymptomatic for 3 years after departure from the area at risk. It is also important to consider recent travel history to areas where not only malaria but also other parasitic infections are endemic.
Leishmania and Babesia have been reported to be transmitted rarely (o5 worldwide) by blood transfusions and could, therefore, potentially be transmitted by stem cells. 12 
Vaccination and donor harvest
An interesting aspect is the eligibility of donors after vaccination. Immunization with nonlive vaccines such as pneumococci, diphtheria toxoid, tetanus toxoid, inactivated poliovaccine and influenza does not influence donor eligibility. Vaccination with live vaccines such as measles, mumps, rubella, varicella and yellow fever should not have been performed during the last 2 weeks. Live polio virus vaccine should, if possible, be avoided. The longest interval between vaccination and donation is required for rabies, where a year should pass after treatment for possible exposure to rabies, but at least a 2-week interval is recommended after prophylactic vaccination.
Transmission of cells with congenital defects
Engraftment of cells with congenital defects might lead to enzyme deficiencies and cause congenital diseases. Theoretically, all congenital diseases originating from bone marrow-derived cells are transmittable, which is of special relevance in pediatric and cord blood transplantation. A special situation exists for thalassemia where an HLAidentical sibling donor is frequently heterozygote for the thalassemia gene defect and a transplantation can result in a conversion from a thalassemia major to a thalassemia minor. Reports of transmission of congenital diseases from 
donor to recipient have been described. Especially in patients with a known family history of congenital diseases, the presence of a congenital disorder has to be excluded. This refers especially to cord blood, where the disease might not be recognized at birth. On the other hand, transplants have been performed from patients with congenital diseases like Gaucher's. 27 In such a patient, stem cells engrafted and no sign of the disease was seen until 196 days after transplant, when he died of relapse. Congenital diseases should be considered as contraindications for stem cell donation, since the possibility frequently exists to use an unrelated donor instead. However, the patient's risk from his underlying disease has to be taken into consideration when exclusion of the only available family donor or related cord blood graft is considered for a low-risk congenital disorder.
Transmission of autoimmunity
Autoimmunity results from a dysregulation of a complex network of cells and molecules occurring on a particular immunogenetic background. Reports of 'transfer' of autoimmunity occurring after allogeneic HSCT should be interpreted with caution, since similar new autoimmunity has also been seen with profound immunosuppression, for example, CAMPATH 1H, 50 and autologous HSCT. 51 These events probably reflect a loss of suppression through T regulator cells (CD4 þ CD25 þ ), are almost always organ or epitope specific, for example, platelet antigens and mostly resolve with time. In addition, it may be difficult to distinguish new autoimmunity from the altered immune phenomena, both clinical and serological, occurring during GVHD.
52
Autoimmune diseases may undergo long-term remission following autologous and allogeneic HSCT. 53 However, autoimmune effector cells and, therefore, autoimmune diseases can be transferred from the donor to a recipient through allogeneic HSCT. Diseases range from a transfer of atopy 29 to myasthenia gravis, 28 thyrotoxicosis of autoimmune type [31] [32] [33] and diabetes mellitus type I. 34 Furthermore, sarcoidosis, 35 celiac disease 36 and autoimmune thrombocytopenia 37 were acquired from allografts. The role of the host in disease expression should also not be forgotten. One case of transfer of SLE antibodies (but not clinical disease) 30 and another of relapse of RA, in which all lymphocytes were of healthy sibling donor origin, 54 emphasize the complexity of immune regulation. The use of an HLA-matched sibling donor who has autoimmunity remains a clinical risk/benefit decision and is the subject of ongoing study.
Transmission of malignant diseases
Two possible scenarios might occur in the transmission of malignant diseases from donors to patients: one involves transplantation of a malignant hematological disease in a new host and the second transfer of graft contaminating malignant cells. As a consequence, malignant cells might 'engraft' as in hematological malignancies or metastasize in the recipient as in solid tumors. Considering the immunodeficiency of the recipient after conditioning and the lack of MHC barriers between donor and recipient, malignant cells may find a permissive environment leading to disease outbreak months to years after HCT. Transmissions of malignant diseases from donors to patients have been reported in the past, most of them inadvertently from subclinical malignant disease or diseases not recognized by the current screening methods. The risk for transmission of tumors and other nonmalignant diseases by HCT can only be estimated, since no prospective reporting is available to date. Considering the frequencies of allogeneic stem cell transplant (42 868 transplants from 1990 to 2001 only in Europe) 2 and the available reports of donor-transmitted malignancies in HCT (three patients reported to date 38, 55, 39 ), a very low incidence is assumed. Of course, these rates do not include secondary malignancies of donor cell origin arising in the recipient after HCT. The occurrence of three donors with hematological malignancies within 99 allogeneic HCT during 1 year (3%) in a single institution as described by Kiss et al 56 contrasts with current knowledge and warrants explanation. Overall incidence may be underestimate, since reporting of such complications might be incomplete and older donors have been used on a large scale only since 1999. All three donors in the Toronto report were above the age of 40 years. In addition, familial aggregation of hematological malignancies becomes frequently manifest only at older age. So far, in our own experience for bone marrow aspirations on almost all related donors (approx. 350 patients with related transplants since 1987 and 25% of them in elderly donors), no occult hematological malignancies were detected (personal experience). However, clearly, systematic evaluation of donor events becomes a necessity.
Several years ago, we reported an inadvertent transmission of acute myeloid leukemia to a patient with chronic myelogenous leukemia. 38 The aleukemic disease was not detectable by CBC including differential and complete chemistry. The infusion of the leukemic graft resulted in complete engraftment of normal donor cells without chromosomal abnormalities. The AML of the donor remained undetectable for four months, but appeared 6 months after HCT with the same morphologic, immunohistologic and cytogenetic abnormalities of the donor's leukemia. Considering that the patient had an additional HLA-identical sibling and no familiar malignancies were known before transplant, only a bone marrow aspiration before transplant might have avoided such a complication. Since then, routine aspirations were performed in our related stem cell donors. Transmission of subcutaneous Tcell lymphoma by a bone marrow transplantation has been reported by Berg et al. 55 The disease was undetectable at the time of transplant, but developed 3 years after transplant in donor and recipients. The finding of identical T-cell clones in the tumors of both sisters implicated the transfer of neoplastic T cells during bone marrow transplantation. In such a situation, no diagnostic test might have avoided this complication. Transfer of hematological malignancies has not been restricted to bone marrow grafts, but has also been reported with peripheralblood stem-cell grafts. 39 
Transmission of donor illness by stem cell transplantation D Niederwieser et al
Kiss et al 56 reported three asymptomatic potential donors with normal complete blood counts, history and physical examination. A 65-year-old donor was diagnosed with smouldering multiple myeloma, a 72-year-old male patient with chronic lymphocytic leukemia and a 42-yearold male with myelodysplastic syndrome. According to the authors, only the routinely performed bone marrow aspiration led to the diagnosis of the malignant disease. However, at least one of them would have been diagnosed by serum protein electrophoresis, which was not part of the screening tests. It may be noted that the three donors were seen within 1 year and in each case the potential donor was discovered to have the same disease as the potential transplant recipient.
Reports of donor-derived malignancies have been more frequent after solid organ transplantation. 57 However, the incidence is very low as revealed from a transplant tumor registry analysis on donor-related malignancies. A total of 21 donor-related malignancies among a cohort of 34 933 cadaveric donors (0.04%) and 108 062 recipients (0.017%) were detected. The cadaveric donor-related tumor mortality rate was 0.007%. 58 Transmission of small-cell lung cancer via renal as well as glioblastoma via liver transplantation has been reported. 40, 41 It should be mentioned that malignancies arising in recipients after HCT or solid organ transplantation are not always caused by transmission of the disease from donor to recipient, but might develop in donor cells as secondary malignancies. 59 The most common donor cell malignancy is PTLD, but other secondary malignancies have also been observed after HCT and solid organ transplantation. 60 
Current practice
Recommendations on donor work-up are available from the major donor and transplant associations and are summarized in Table 2 . Some are specific for unrelated donors others include related, unrelated and autologous HCT. While the contents are similar, recommendations focus on different aspects. Medical history and physical examination are specified in some recommendations and some refer to local regulations. There is agreement on performing chest X-ray, ECG and full blood count and less agreement on coagulation tests and biochemical profiles.
While screening tests for infections are well defined and similar to those used for blood transfusions, blood chemistry and work-up for malignancies (especially nonhematological malignancies) are not standardized or lacking and there is no age-adapted donor screening. Some of the transplant centers, including ours, use bone marrow aspiration on related donors to exclude occult hematological malignancies.
Conclusions
While transmission of infectious diseases or pathogens might be a more frequent problem, transmissions of congenital, autoimmune or malignant disease is quite uncommon. With the use of older donors (425% of all HCT are performed in elderly patients), the risk might change considerably and increased attention should be paid to occult malignancies or infections.
Can we improve the screening of stem cell donors without it being too expensive and should screening be different in older donors?
One of the fundamental tools in screening donors is careful assessment of the donor's medical history, which should always include family, travel, vaccination, smoking, blood transfusion and donation, infection, pregnancy, allergy, autoimmune, vaccination and tumor history ( Table 2) . Identification of donors at high risk for transmittable infections is essential. Testing for HIV, HBV, HCV, syphilis and CMV is mandatory. In EBVseronegative patients, it is recommended that the donor is tested for EBV since existing data now suggest that an EBV-positive donor should not be used for an EBVnegative recipient of an unrelated or mismatched SCT, due to the risk for PTLD. In countries with high incidences of particular infectious diseases, the screening panel might be modified according to local experiences.
Patients with leukemia and a history of leukemia in the family should be evaluated more carefully, especially if they are older than 55 years of age. Familial aggregation of many hematological malignancies have been reported. [62] [63] [64] [65] Physical examinations are of crucial importance in elderly donors and able to detect or raise suspicion for a variety of malignant and nonmalignant diseases. Coagulation tests are useful and ECG as well as chest X-ray should be mandatory for the safety of the donor and the recipient. In order to exclude malignant hematological diseases, a complete blood count with a manual (not automatic) differential should be performed. By including a protein electrophoresis in the screening analyses, multiple myelomas and other gammopathies might be detected, as well as hints of light-chain myelomas. In addition liver diseases and immunodeficiency might be recognized. In our opinion, cost-benefit analysis does not justify Bence-Jones urine determinations in every donor, except in patients at risk.
The use of bone marrow aspirations as a screening method is controversial. Despite having used this test since 1987 in our program, no donor was identified having a malignant disease not recognized by routine screening. Aleukemic leukemias in early stages are so infrequent that the cost-benefit relation does not justify a bone marrow aspiration for screening related donors. In addition only one of the three donors of Kiss et al may have been missed without bone marrow aspiration, since in one patient myeloma should have been detected by electrophoresis and in the other no differential was reported despite a leukocyte count of 10.1 Â 10 9 /l. In summary, bone marrow aspiration may not be an adequate screening method. If however, results are borderline or donors reveal a familiar history of malignancies, bone marrow aspiration should be performed in order to exclude a hematological malignant disease.
In our opinion, screening for frequent hematological and nonhematological malignancies is justified in older donors (455 years) for the safety of the recipient but even more for the safety of the donor. This includes a chest CT scan for lung cancer when a history of more than 10 years of smoking is present and a physical examination for breast cancer. Considering the frequencies of colon and prostatic cancer in elderly individuals, occult blood and prostatespecific antigen should be determined. In contrast to blood transfusions, stem cells from donors with abnormal findings might still be acceptable for HCT when no other options are available. However, how should donors be handled with abnormal findings and which abnormalities are acceptable? Any abnormal finding discovered during donor evaluation has to be reported to the donor, who of course has the right to decline donation and keep the reason confidential. It also puts obligations on the screening center to follow-up the donor and/or recommend adequate medical care.
Abnormal findings that may increase the recipient's risk will be reported to the recipient, who will be appropriately counseled as to the potential impact on outcome, and written informed consent obtained from recipient and donor. Factors such as donor provenance (related or unrelated), stem cell source (PBMC or cord blood), immune status of the recipient and underlying disease are important determinants in this process. However, relative and absolute contraindications remain (Table 3) . Congenital genetic disorders can be excluded by a careful medical history and, in families at risk, specific diagnostic procedures have to be undertaken. Screening of the cord blood after delivery and, if required, screening of the mother is recommended. If a congenital disease is present, the unrelated donor has to be excluded. In contrast, congenital diseases might be a relative contraindication for donation in related settings. With regard to hepatitis, malaria and similar infections, the patient's risk of his/her underlying disease must be balanced against the delay or cancellation of the HCT. Of course, the patient's viral status is also an important factor to take into account.
Finally, a prospective evaluation of donor-transmitted complications within the established registries is urgently needed. Systematic monitoring of incidence, severity and outcome of donor-related complications is recommended to allow possible changes in donor screening. 
